Volkmar Muller - Publications

Axillary surgery in early breast cancer: real-world analysis of the INSEMA-trial at three certified university breast cancer centers in Germany regarding the omission of sentinel lymph node biopsy.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: July 24, 2025

Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer.

Journal: Cancer treatment reviews

Published: July 17, 2024

Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review.

Journal: Cancer treatment reviews

Published: December 20, 2022

Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry.

Journal: ESMO open

Published: January 23, 2022

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.

Journal: ESMO open

Published: August 04, 2021

First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study.

Journal: Breast (Edinburgh, Scotland)

Published: May 20, 2021

Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 10, 2021

Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients.

Journal: Breast cancer research and treatment

Published: September 14, 2019

Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial.

Journal: Cancers

Published: July 29, 2019

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry.

Journal: Cancers

Published: October 28, 2018

Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto.

Journal: Breast cancer research : BCR

Published: August 22, 2018

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.

Journal: BMC cancer

Published: July 31, 2017